Journal of Cardiovascular Pharmacology · 2001 · 11 citations · 58 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical PharmacologyPharmacodynamicsCardiac PharmacotherapyCardiovascular DiseaseCardiovascular PharmacologyCardiovascular PhysiologyHeart FailureHypertension PharmacotherapyAntihypertensive PharmacologyBlood PressureCardiac IndexCardiac Performance IndicesEndothelin Receptor AntagonistsHeart RateMyocardial Performance IndexSystolic Blood Pressure
Evidence suggests that endothelin receptor antagonists may have therapeutic potential for the chronic treatment of heart failure. In the current study, the effects of an orally active mixed endothelin-A/endothelin-B (ETA /ETB ) receptor antagonist (enrasentan) were assessed in a model of cardiac hypertrophy and dysfunction (spontaneously hypertensive stroke prone rats) maintained on a high-salt/high-fat diet. Echocardiography was used to quantify cardiac performance and left ventricular dimensions. Enrasentan (1,200 and 2,400 parts per million in the high-salt/high-fat diet) had no significant effects on body weight and systolic blood pressure. However, increases in heart rate were not observed in the enrasentan-treated groups at 12 weeks (p < 0.05). Enrasentan-treated groups exhibited significantly improved survival (90-95% vs. 30% [control rats] at 18 weeks; p < 0.001). Enrasentan treatments also increased stroke volume (at 8, 12, and 16 weeks) and cardiac index (at 8 and 16 weeks) 33-50% and 45-63%, respectively. Enrasentan treatments reduced the relative wall thickness (14-27% at 8 and 12 weeks), ratio of left ventricular mass to body weight (20% at 12 weeks), and ratio of terminal heart weight to body weight (16-23%, p < 0.05). Finally, circulating aldosterone concentration (54-57%) and proANF fragment (33%) were reduced in enrasentan-treated groups (54-57% and 33%, respectively). Mixed ETA /ETB receptor antagonism improves cardiac performance and attenuates ventricular remodeling and premature mortality in an aggressive hypertension model.
58
A novel potent vasoconstrictor peptide produced by vascular endothelial cells
Masashi Yanagisawa, Hiroki Kurihara, Sadao Kimura et al. · Nature · 1988 · 10.8K citations · Full text
H E Shubeita, Patrick M. McDonough, Adrienne N. Harris et al. · Journal of Biological Chemistry · 1990 · 643 citations · Full text
Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
Satoshi Sakai, Takashi Miyauchi, Masahiko Kobayashi et al. · Nature · 1996 · 627 citations
Medicine, Cardiology, Pharmacology +15
Endothelin in human congestive heart failure.
Chao Wei, A. Lerman, Richard J. Rodeheffer et al. · Circulation · 1994 · 588 citations